Emerging evidence highlights biomarkers such as PD-L1, MSI, HER-2, tumor mutation burden (TMB), and Epstein-Barr virus (EBV) as vital tools for detecting early tumors, evaluating prognosis, monitoring tumor burden, predicting drug resistance, and tailoring therapy decisions (7). Here, ERBB2 is linked to neoplasm.